Brief Summary
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Protocol Interventions
Drug: 64Cu-SAR-bisPSMA, Drug: 67Cu-SAR-bisPSMA